Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.67 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.67 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laudanosine SCHEMBL466528 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL30816021 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL466529 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL29822950 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL11398962 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346112 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL11398960 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346139 | 0.95 | LMNA (0.90) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346180 | 0.95 | LMNA (0.90) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Dimethylgrisabine SCHEMBL30735570 | 0.92 | LMNA (0.84) | LMNAKDM4EALDH1A1HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086696-A2 | APPARATUS AND METHODS FOR CONTINUOUS FLOW SYNTHESIS OF CISATRACURIUM | ODH IP Corp. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-107778234-B | Preparation method of neuromuscular blocker intermediate | 四川科瑞德制药股份有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20110185796-A1 | CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF | CHEMAGIS LTD. (IL) | 2011-08-04 | — | — | US | disclosed |
| WO-2009133556-A2 | CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF | CHEMAGIS LTD. (IL) | 2009-11-05 | — | — | WO | disclosed |
| EP-0971898-B1 | SUBSTITUTED ISOQUINOLINES AS ULTRA SHORT ACTING NEUROMUSCULAR BLOCKERS | AVERA PHARMACEUTICALS INC (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1526130-A1 | Substituted isoquinolines as ultra short acting neuromuscular blockers | Avera Pharmaceuticals, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6177445-B1 | MUSCLE RELAXANTS | GLAXO WELLCOME INC. | 2001-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110185796-A1 | CISATRACURIUM DERIVATIVES, PREPARATION AND USES THEREOF | CHRNA5, GAP43, CHRNA3 | LMNA 1771/4885KDM4E 2186/4885ALDH1A1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.